Procyon Advisors LLC acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 24,647 shares of the biopharmaceutical company’s stock, valued at approximately $263,000.
Other institutional investors have also bought and sold shares of the company. Xponance Inc. increased its stake in Amicus Therapeutics by 5.3% during the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares in the last quarter. American International Group Inc. raised its holdings in shares of Amicus Therapeutics by 0.9% in the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after acquiring an additional 1,298 shares in the last quarter. Arizona State Retirement System lifted its position in Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares during the last quarter. Diversified Trust Co lifted its holdings in shares of Amicus Therapeutics by 3.8% during the 3rd quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 2,698 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 2,737 shares in the last quarter.
Amicus Therapeutics Stock Up 1.8 %
Shares of NASDAQ FOLD opened at $10.50 on Thursday. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The stock has a 50 day moving average price of $11.15 and a 200 day moving average price of $10.55. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -21.43 and a beta of 0.69. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on FOLD. Jefferies Financial Group began coverage on Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 price objective on the stock. Morgan Stanley decreased their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. cut their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.
Read Our Latest Analysis on FOLD
Insider Buying and Selling
In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $9,398,532.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 22,500 shares of company stock valued at $244,875 over the last quarter. 2.20% of the stock is currently owned by company insiders.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Stories
- Five stocks we like better than Amicus Therapeutics
- Best Stocks Under $5.00
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- About the Markup Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.